Search

Your search keyword '"Bruera, Gemma"' showing total 142 results
Start Over Author "Bruera, Gemma"
142 results on '"Bruera, Gemma"'

1. Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases

Author

Guadagni, Stefano, Masedu, Francesco, Fiorentini, Giammaria, Sarti, Donatella, Fiorentini, Caterina, Guadagni, Veronica, Apostolou, Panagiotis, Papasotiriou, Ioannis, Parsonidis, Panagiotis, Valenti, Marco, Ricevuto, Enrico, Bruera, Gemma, Farina, Antonietta R., Mackay, Andrew R., and Clementi, Marco

Published
2022
Full Text
View/download PDF

2. Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study

Author

Guadagni, Stefano, Clementi, Marco, Mackay, Andrew R., Ricevuto, Enrico, Fiorentini, Giammaria, Sarti, Donatella, Palumbo, Paola, Apostolou, Panagiotis, Papasotiriou, Ioannis, Masedu, Francesco, Valenti, Marco, Giordano, Aldo Victor, and Bruera, Gemma

Published
2020
Full Text
View/download PDF

8. Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments

Author

Bruera,Gemma and Ricevuto,Enrico

Subjects
Pharmacogenomics and Personalized Medicine
Abstract

Gemma Bruera,1,2 Enrico Ricevuto1,2 On behalf of Oncology Network ASL1 Abruzzo1Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy; 2Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, ItalyCorrespondence: Gemma BrueraOncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Via Vetoio, L’Aquila 67100, ItalyTel +39 0862368746Fax +39 0862368308Email gemma.gbb@gmail.comAbstract: Evolving intensiveness of colorectal cancer (CRC) treatment, including chemotherapeutics and targeted agents associations, in adjuvant and metastatic CRC (MCRC) settings, increased overall survival (OS) with individual variability of toxicity. Pharmacogenomic guidelines recommended pre-treatment identification of at-risk patients suggesting dose adjustment of fluoropyrimidines based on dihydropyrimidine dehydrogenase (DPYD), and irinotecan on UDP glucuronosyl-transferase 1 family polypeptide A1 (UGT1A1) genetic variants, but they are poorly applied in clinical practice. This review highlighted clinically validated pharmacogenetic markers, to underline the need of their implementation in the multidisciplinary molecular board for individual CRC patients in clinical practice. Five clinically relevant DPYD variants with different prevalence impair enzymatic effectiveness and significantly increase toxicity: c.1236 G>A (c.1129– 5923 C>G, HapB3), 4.1– 4.8%; c.1679 T>G (DPYD*13), c.1905+1G>A (DPYD*2A), c.2846 A>T, c.2194 A>T (DPYD*6) 1% each. c.1679T>G and c.1905+1G>A are most deleterious on DPD effectiveness, moderately reduced in c.1236/HapB3 and c.2846A>T. Cumulatively, these variants explain approximately half of the estimated 10– 15% fluoropyrimidine-related gastrointestinal and hematological toxicities due to DPD. Prevalent UGT1A1 gene [TA]7TAA promoter allelic variant UGT1A1*28, characterized by an extra TA repeat, is associated with low transcriptional and reduced enzymatic effectiveness, decreased SN38 active irinotecan metabolite glucuronidation, vs wild-type UGT1A1*1 [A(TA)6TAA]. Homozygote UGT1A1*28 alleles patients are exposed to higher hematological and gastrointestinal toxicities, even more than heterozygote, at > 150 mg/m2 dose. Dose reduction is recommended for homozygote variant. Wild-type UGT1A1*28 alleles patients could tolerate increased doses, potentially affecting favorable outcomes. Implementation of up-front evaluation of the five validated DPYD variants and UGT1A1*28 in the multidisciplinary molecular tumor board, also including CRC genetic characterization, addresses potential treatments with fluoropyrimidines and irinotecan associations at proper doses and schedules, particularly for early CRC, MCRC patients fit for intensive regimens or unfit for conventional regimens, requiring treatment modulations, and also for patients who experience severe, unexpected toxicities. Integration of individual evaluation of toxicity syndromes (TS), specifically limiting TS (LTS), an innovative indicator of toxicity burden in individual patients, may be useful to better evaluate relationships between pharmacogenomic analyses with safety profiles and clinical outcomes.Keywords: colorectal cancer, personalized treatments, pharmacogenomics

Published
2020

9. Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A

Author

Guadagni, Stefano, primary, Farina, Antonietta Rosella, additional, Cappabianca, Lucia Annamaria, additional, Sebastiano, Michela, additional, Maccarone, Rita, additional, Zelli, Veronica, additional, Clementi, Marco, additional, Chiominto, Alessandro, additional, Bruera, Gemma, additional, Ricevuto, Enrico, additional, Fiorentini, Giammaria, additional, Sarti, Donatella, additional, and Mackay, Andrew Reay, additional

Published
2020
Full Text
View/download PDF

12. 846421_supplementary_mater – Supplemental material for Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers

Author

Bruera, Gemma, Massacese, Silvia, Pepe, Francesco, Malapelle, Umberto, Mas, Antonella Dal, Ciacco, Eugenio, Calvisi, Giuseppe, Troncone, Giancarlo, Simmaco, Maurizio, and Ricevuto, Enrico

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, 846421_supplementary_mater for Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers by Gemma Bruera, Silvia Massacese, Francesco Pepe, Umberto Malapelle, Antonella Dal Mas, Eugenio Ciacco, Giuseppe Calvisi, Giancarlo Troncone, Maurizio Simmaco and Enrico Ricevuto in Therapeutic Advances in Medical Oncology

Published
2019
Full Text
View/download PDF

13. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

Author

Bruera Gemma, Cannita Katia, Di Giacomo Daniela, Lamy Aude, Troncone Giancarlo, Dal Mas Antonella, Coletti Gino, Frébourg Thierry, Sabourin Jean, Tosi Mario, Ficorella Corrado, and Ricevuto Enrico

Subjects
disease extension, intensive regimen, KRAS mutations, metastatic colorectal cancer, triplet chemotherapy plus bevacizumab, Medicine
Abstract

Abstract Background Bevacizumab (BEV) plus triplet chemotherapy can increase efficacy of first-line treatment of metastatic colorectal cancer (MCRC), particularly integrated with secondary liver surgery in liver-limited (L-L) patients. The prognostic value of the KRAS genotype in L-L and other or multiple metastatic (O/MM) MCRC patients treated with the FIr-B/FOx regimen was retrospectively evaluated. Methods Tumoral and metastatic samples were screened for KRAS codon 12 and 13 and BRAF mutations by SNaPshot and/or direct sequencing. Fit MCRC patients 2, days 1, 2, 8, 9, 15, 16, 22 and 23; irinotecan (CPT-11) 160 mg/m2 plus BEV 5 mg/kg, days 1, 15; oxaliplatin (OXP) 80 mg/m2, days 8, 22; every 4 weeks. MCRC patients were classified as L-L and O/MM. Activity and efficacy were evaluated and compared using log-rank test. Results In all, 59 patients were evaluated: 31 KRAS wild-type (53%), 28 KRAS mutant (47%). At 21.5 months median follow-up, objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were, respectively: KRAS wild-type 90%, 14 months, 38 months; KRAS mutant 67%, 11 months, 20 months. PFS and OS were not significantly different. PFS and OS were significantly different in L-L compared to O/MM evaluable patients. In KRAS wild-type patients, clinical outcome of 12 L-L compared to 18 O/MM was significantly different: PFS 21 versus 12 months and OS 47 versus 28 months, respectively. In KRAS mutant patients, the clinical outcome of 13 L-L compared to 14 O/MM was not significantly different: PFS 11 months equivalently and OS 39 versus 19 months, respectively. Conclusions The KRAS genotype wild-type and mutant does not significantly affect different clinical outcomes for MCRC patients treated with the first-line FIr-B/FOx intensive regimen. KRAS wild-type patients with L-L disease may achieve a significantly prolonged clinical outcome due to integration with secondary liver surgery, with respect to KRAS mutant patients.

Published
2012
Full Text
View/download PDF

14. Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study

Author

Guadagni, Stefano, primary, Fiorentini, Giammaria, additional, De Simone, Michele, additional, Masedu, Francesco, additional, Zoras, Odisseas, additional, Mackay, Andrew Reay, additional, Sarti, Donatella, additional, Papasotiriou, Ioannis, additional, Apostolou, Panagiotis, additional, Catarci, Marco, additional, Clementi, Marco, additional, Ricevuto, Enrico, additional, and Bruera, Gemma, additional

Published
2019
Full Text
View/download PDF

15. Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: a retrospective study

Author

Guadagni, Stefano, primary, Fiorentini, Giammaria, additional, Palumbo, Paola, additional, Masedu, Francesco, additional, Ricevuto, Enrico, additional, Bruera, Gemma, additional, Deraco, Marcello, additional, Kusamura, Shigeki, additional, Sarti, Donatella, additional, Fiorentini, Caterina, additional, Gailhofer, Sabine, additional, and Clementi, Marco, additional

Published
2019
Full Text
View/download PDF

16. Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study

Author

Guadagni, Stefano, primary, Fiorentini, Giammaria, additional, Mambrini, Andrea, additional, Masedu, Francesco, additional, Valenti, Marco, additional, Mackay, Andrew Reay, additional, Sarti, Donatella, additional, Ricevuto, Enrico, additional, Clementi, Marco, additional, Catarci, Marco, additional, Lazzarin, Gianni, additional, and Bruera, Gemma, additional

Published
2019
Full Text
View/download PDF

18. Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers

Author

Bruera, Gemma, primary, Massacese, Silvia, additional, Pepe, Francesco, additional, Malapelle, Umberto, additional, Dal Mas, Antonella, additional, Ciacco, Eugenio, additional, Calvisi, Giuseppe, additional, Troncone, Giancarlo, additional, Simmaco, Maurizio, additional, and Ricevuto, Enrico, additional

Published
2019
Full Text
View/download PDF

19. 'Poker' association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study

Author

Marchetti Paolo, Mancini Maria, De Galitiis Federica, Tudini Marianna, Baldi Paola, Cannita Katia, Santomaggio Alessandra, Bruera Gemma, Antonucci Adelmo, Ficorella Corrado, and Ricevuto Enrico

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background This phase II study investigated efficacy and safety of weekly alternating Bevacizumab (BEV)/Irinotecan (CPT-11) or Oxaliplatin (OHP) associated to weekly 5-Fluorouracil (5-FU) in first line treatment of metastatic colorectal carcinoma (MCRC). Methods Simon two-step design: delta 20% (p0 50%, p1 70%), power 80%, α 5%, β 20%. Projected objective responses (ORR): I step, 8/15 patients (pts); II step 26/43 pts. Schedule: weekly 12 h-timed-flat-infusion/5-FU 900 mg/m2, days 1-2, 8-9, 15-16, 22-23; CPT-11 160 mg/m2 plus BEV 5 mg/kg, days 1,15; OHP at three dose-levels, 60-70-80 mg/m2, days 8, 22; every 4 weeks. Results Fifty consecutive, unselected pts < 75 years were enrolled: median age 63; young-elderly (yE) 24 (48%); liver metastases (LM) 33 pts, 66% Achieved OHP recommended dose, 80 mg/m2. ORR 82% intent-to-treat and 84% as-treated analysis. Median progression-free survival 12 months. Equivalent efficacy was obtained in yE pts. Liver metastasectomies were performed in 26% of all pts and in 39% of pts with LM. After a median follow-up of 21 months, median overall survival was 28 months. Cumulative G3-4 toxicities per patient: diarrhea 28%, mucositis 6%, neutropenia 10%, hypertension 2%. They were equivalent in yE pts. Limiting toxicity syndromes (LTS), consisting of the dose-limiting toxicity, associated or not to G2 or limiting toxicities: 44% overall, 46% in yE. Multiple versus single site LTS, respectively: overall, 24% versus 20%; yE pts, 37.5% versus 8%. Conclusion Poker combination shows high activity and efficacy in first line treatment of MCRC. It increases liver metastasectomies rate and can be safely administered. Trial registration Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali (OsSC) Agenzia Italiana del Farmaco (AIFA) Numero EudraCT 2007-004946-34

Published
2010
Full Text
View/download PDF

20. KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy

Author

Bruera, Gemma, primary, Pepe, Francesco, additional, Malapelle, Umberto, additional, Pisapia, Pasquale, additional, Mas, Antonella Dal, additional, Di Giacomo, Daniela, additional, Calvisi, Giuseppe, additional, Troncone, Giancarlo, additional, and Ricevuto, Enrico, additional

Published
2018
Full Text
View/download PDF

21. Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

Author

Bruera, Gemma, primary, Massacese, Silvia, additional, Pepe, Francesco, additional, Malapelle, Umberto, additional, Dal Mas, Antonella, additional, Ciacco, Eugenio, additional, Calvisi, Giuseppe, additional, Marchetti, Paolo, additional, Troncone, Giancarlo, additional, Simmaco, Maurizio, additional, and Ricevuto, Enrico, additional

Published
2018
Full Text
View/download PDF

22. Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer

Author

Bruera, Gemma, primary, Di Staso, Mario, additional, Bonfili, Pierluigi, additional, Galvano, Antonio, additional, Manetta, Rosa, additional, Coletti, Gino, additional, Vicentini, Roberto, additional, Guadagni, Stefano, additional, Ficorella, Corrado, additional, Di Cesare, Ernesto, additional, Russo, Antonio, additional, and Ricevuto, Enrico, additional

Published
2018
Full Text
View/download PDF

23. KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease

Author

Tessitore, Alessandra, primary, Bruera, Gemma, additional, Mastroiaco, Valentina, additional, Cannita, Katia, additional, Cortellini, Alessio, additional, Cocciolone, Valentina, additional, Dal Mas, Antonella, additional, Calvisi, Giuseppe, additional, Zazzeroni, Francesca, additional, Ficorella, Corrado, additional, Ricevuto, Enrico, additional, and Alesse, Edoardo, additional

Published
2018
Full Text
View/download PDF

24. Intensive first-line triplet chemotherapy plus cetuximab FIr-C/FOx-C in RAS wild-type MCRC: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

Author

Bruera, Gemma, primary, Massacese, Silvia, additional, Dal Mas, Antonella, additional, Ficorella, Corrado, additional, Ciacco, Eugenio, additional, Calvisi, Giuseppe, additional, Simmaco, Maurizio, additional, and Ricevuto, Enrico, additional

Published
2018
Full Text
View/download PDF

25. Abstract A052: Predictive wild-typeRAS/BRAFand pharmacogenetic biomarkers drive selection of metastatic colorectal cancer patients fit for intensive first-line FIr-C/FOx-C schedule adding cetuximab to triplet chemotherapy

Author

Bruera, Gemma, primary, Massacese, Silvia, additional, Dal Mas, Antonella, additional, Ficorella, Corrado, additional, Ciacco, Eugenio, additional, Calvisi, Giuseppe, additional, Simmaco, Maurizio, additional, and Ricevuto, Enrico, additional

Published
2018
Full Text
View/download PDF

28. Differential clinical outcome according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing of metastatic colorectal cancer patients treated with first line FIr-B/FOx adding bevacizumab to triplet chemotherapy

Author

Bruera, Gemma, primary, Pepe, Francesco, additional, Malapelle, Umberto, additional, Pisapia, Pasquale, additional, Dal Mas, Antonella, additional, Calvisi, Giuseppe, additional, Troncone, Giancarlo, additional, and Ricevuto, Enrico, additional

Published
2017
Full Text
View/download PDF

29. Differential clinical outcome of metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing.

Author

Bruera, Gemma, primary, Pepe, Francesco, additional, Malapelle, Umberto, additional, Pisapia, Pasquale, additional, Dal Mas, Antonella, additional, Marchetti, Paolo, additional, Calvisi, Giuseppe, additional, Troncone, Giancarlo, additional, and Ricevuto, Enrico, additional

Published
2017
Full Text
View/download PDF

30. Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.

Author

Bruera, Gemma, primary, Malapelle, Umberto, additional, Pepe, Francesco, additional, Pisapia, Pasquale, additional, Dal Mas, Antonella, additional, Calvisi, Giuseppe, additional, Troncone, Giancarlo, additional, and Ricevuto, Enrico, additional

Published
2017
Full Text
View/download PDF

34. Dose-Dense Nonpegylated Liposomal Doxorubicin and Docetaxel Combination in Breast Cancer: Dose-Finding Study

Author

Ricevuto, Enrico, primary, Cocciolone, Valentina, additional, Mancini, Maria, additional, Cannita, Katia, additional, Romano, Silvio, additional, Bruera, Gemma, additional, Pelliccione, Michela, additional, Adinolfi, Maria Ilaria, additional, Ciccozzi, Antonietta, additional, Bafile, Alberto, additional, Penco, Maria, additional, and Ficorella, Corrado, additional

Published
2015
Full Text
View/download PDF

36. Prognostic relevance of KRAS genotype and the prevalent C.35 G > a mutation in metastatic colorectal cancer (MCRC) patients fitting for intensive FIr-B/FOx triplet chemotherapy plus bevacizumab.

Author

Bruera, Gemma, primary, Cannita, Katia, additional, Tessitore, Alessandra, additional, Cortellini, Alessio, additional, Sabourin, Jean Christophe, additional, Tosi, Mario, additional, Frébourg, Thierry, additional, Alesse, Edoardo, additional, Ficorella, Corrado, additional, and Ricevuto, Enrico, additional

Published
2014
Full Text
View/download PDF

41. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines

Author

MARAMPON, FRANCESCO, primary, GRAVINA, GIOVANNI LUCA, additional, POPOV, VALDIMIR M., additional, SCARSELLA, LUCA, additional, FESTUCCIA, CLAUDIO, additional, LA VERGHETTA, MARIA EMILIA, additional, PARENTE, SILVIA, additional, CERASANI, MANUELA, additional, BRUERA, GEMMA, additional, FICORELLA, CORRADO, additional, RICEVUTO, ENRICO, additional, TOMBOLINI, VINCENZO, additional, DI CESARE, ERNESTO, additional, and ZANI, BIANCA MARIA, additional

Published
2013
Full Text
View/download PDF

43. KRAS Genotype and the Prevalent C.35 G > A Mutation Affect Significantly Worse Prognosis of Metastatic Colorectal Cancer (MCRC) Patients Fitting for Intensive Fir-B/Fox Triplet Chemotherapy Plus Bevacizumab

Author

Cannita Katia, Sabourin Jean Christophe, Ficorella Corrado, Bruera Gemma, Tosi Mario, Alesse Edoardo, Frebourg Thierry, Ricevuto Enrico, Tessitore Alessandra, and Cortellini Alessio

Subjects
Oncology, medicine.medical_specialty, Bevacizumab, business.industry, Colorectal cancer, Hematology, Affect (psychology), medicine.disease, Chemotherapy regimen, Triplet chemotherapy, Internal medicine, Genotype, Mutation (genetic algorithm), medicine, business, medicine.drug
Published
2014

45. Worse prognosis of KRAS C.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with first-line triplet chemotherapy plus bevacizumab (FIr-B/FOx) and post-progression.

Author

Bruera, Gemma, primary, Cannita, Katia, additional, Di Giacomo, Daniela, additional, Lamy, Aude, additional, Giordano, Aldo Victor, additional, Vicentini, Roberto, additional, Marchetti, Paolo, additional, Frébourg, Thierry, additional, Sabourin, Jean-Christophe, additional, Tosi, Mario, additional, Alesse, Edoardo, additional, Ficorella, Corrado, additional, and Ricevuto, Enrico, additional

Published
2013
Full Text
View/download PDF

46. Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

Author

Bruera, Gemma, primary, Cannita, Katia, additional, Di Giacomo, Daniela, additional, Lamy, Aude, additional, Frébourg, Thierry, additional, Sabourin, Jean Christophe, additional, Tosi, Mario, additional, Alesse, Edoardo, additional, Ficorella, Corrado, additional, and Ricevuto, Enrico, additional

Published
2013
Full Text
View/download PDF

48. P-0266 Worse Prognosis of Kras C.35 G>A Mutant Mcrc Patients Treated with Intensive Triplet Chemotherapy Plus Bevacizumab (FIR-B/FOX)

Author

Bruera, Gemma, primary, Cannita, Katia, additional, Di Giacomo, Daniela, additional, Lamy, Aude, additional, Troncone, Giancarlo, additional, Dal Mas, Antonella, additional, Coletti, Gino, additional, Frébourg, Thierry, additional, Sabourin, Jean Christophe, additional, Tosi, Mario, additional, Ficorella, Corrado, additional, and Ricevuto, Enrico, additional

Published
2012
Full Text
View/download PDF

49. Different clinical outcome of metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to KRAS genotype and disease extension.

Author

Bruera, Gemma, primary, Cannita, Katia, additional, Di Giacomo, Daniela, additional, Lamy, Aude, additional, Troncone, Giancarlo, additional, Dal Mas, Antonella, additional, Coletti, Gino, additional, Frébourg, Thierry, additional, Sabourin, Jean-Christophe, additional, Tosi, Mario, additional, Ficorella, Corrado, additional, and Ricevuto, Enrico, additional

Published
2012
Full Text
View/download PDF

50. Worse prognosis of KRAS C.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).

Author

Bruera, Gemma, primary, Cannita, Katia, additional, Di Giacomo, Daniela, additional, Lamy, Aude, additional, Troncone, Giancarlo, additional, Dal Mas, Antonella, additional, Coletti, Gino, additional, Frébourg, Thierry, additional, Sabourin, Jean-Christophe, additional, Tosi, Mario, additional, Ficorella, Corrado, additional, and Ricevuto, Enrico, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results